Research programme: histamine H3 receptor antagonists - Merck/Banyu

Drug Profile

Research programme: histamine H3 receptor antagonists - Merck/Banyu

Alternative Names: 5R

Latest Information Update: 29 Aug 2011

Price : $50

At a glance

  • Originator Banyu; Merck & Co
  • Class Benzofurans; Quinazolinones
  • Mechanism of Action Histamine H3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported CNS disorders

Most Recent Events

  • 29 Aug 2011 No development reported - Preclinical for CNS disorders in Japan (PO)
  • 21 Aug 2008 Preclinical trials in CNS disorders in Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top